Self-Expanding Versus Balloon Expanding Coronary Stents in Intervention of the Degenerated Saphenous Vein Graft: Memmingen Coronary Artery Bypass Stenosis Trial (MECAST)
Table 1
Patient characteristics.
SExS (n = 51)
BExS (n = 56)
value
n SD
n (%)
MeanSD
n SD
n (%)
MeanSD
Sex
Female
9
17.6
7
12.5
0.458
Male
425.05
82.4
49
87.5
Age
761.21
741.16
0.360
ACS
Total
21
41.2
28
50.0
0.362
STEMI
3
5.9
2
3.6
0.477
NSTEMI
187.91
35.3
26
46.4
0.491
Diabetes
Medication
163.69
31.4
163.69
28.6
0.506
Insulin
9
17.6
8
14.3
EF
45
50
0.069
PAOD
173.87
33.3
193.95
33.9
0.948
Renal insufficiency
Low (creatinine clearance <90 mg/mmol)
183.87
35.3
153.59
26.8
0.181
Moderate (creatinine clearance <60 mg/mmol)
62.38
11.8
3
5.4
Severe (creatinine clearance <30 mg/mmol)
11.00
2.0
0
0
Dialysis
11.00
2.0
3
5.4
Age of CABG
17.0
16 1.04
0.490
History of previous CABG intervention
111.96
21.6
142.38
25.0
0.616
Values are number (n)standard deviation (SD), number (%) or meanstandard deviation. A value <0.05 is considered significant. SExS = self-expanding drug eluting stent; BExS = balloon expanding drug eluting stent; ACS = acute coronary syndrome; EF = ejection fraction; PAOD = peripheral artery occlusive disease; CABG = coronary artery bypass graft.
